Collaboration Revenue (Tables)

3 Months Ended

Mar. 31, 2013

Collaboration Revenue Disclosure [Abstract]

collaboration revenue with related party

The collaboration revenue the Company earned from Sanofi, as detailed below, consisted primarily of reimbursement for research and development expenses that the Company incurred, recognition of the Company's share of losses in connection with Sanofi's commercialization of ZALTRAP^®, and recognition of revenue related to non-refundable up-front payments.

	Three months ended March 31,
Sanofi Collaboration Revenue:	2013			2012
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	$	(7,789	)	$	(3,705	)
Reimbursement of Regeneron research and development and other expenses	2,563			2,820
Recognition of deferred revenue related to up-front payments	1,384			2,483
Total ZALTRAP	(3,842		)	1,598
Antibody:
Reimbursement of Regeneron research and development expenses	100,554			80,855
Recognition of deferred revenue related to up-front and other payments	2,162			2,153
Recognition of revenue related to VelociGene agreement	399			399
Total Antibody	103,115			83,407
Total Sanofi collaboration revenue	$	99,273		$	85,005

Collaboration revenue

The collaboration revenue the Company earned from Bayer HealthCare is detailed below:

	Three months ended March 31,
Bayer HealthCare Collaboration Revenue	2013		2012
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	6,362
Cost-sharing of Regeneron EYLEA development expenses	5,971		$	10,506
Reimbursement of other Regeneron EYLEA expenses	597
Recognition of deferred revenue related to up-front and other milestone payments	1,977		1,977
	$	14,907	$	12,483